LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATARA BIOTHERAPEUTICS, INC. (ATRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On January 16, 2025, Atara disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) of the Company’s Epstein-Barr treatment, tabelecleucel (also referred to as EBVALLO), and that the application would not be approved in its current form, stating that “[t]he CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO.”
On this news, Atara’s stock price fell $5.33, or 40.5%, to close at $7.83 per share on January 16, 2025, thereby injuring investors.
Then, on January 21, Atara disclosed that the FDA had “placed a clinical hold on Atara’s active Investigational New Drug (IND) applications” due to “inadequately addressed GMP [good manufacturing practice] compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the [CRL]” issued in connection with the tabelecleucel BLA.
On this news, Atara’s stock price fell $0.52, or 7.9%, to close at $6.05 per share on January 21, 2025.
Finally, on January 12, 2026, Atara disclosed that the FDA had issued another CRL regarding the resubmitted tabelecleucel BLA stating that “[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form” because “the single arm ALLELE trial . . . is no longer considered to be adequate to provide evidence of effectiveness for accelerated approval” and “the trial’s interpretability is confounded due to trial study design, conduct, and analysis.”
On this news, Atara’s stock price fell $7.79, or 56.99%, to close at $5.88 per share on January 12, 2026, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Atara should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com
